To assess whether remote application of photobiomodulation (PBM) is effective in reducing clinical signs of Parkinson's disease (PD).
Background:
PD is a progressive neurodegenerative disease for which there is no cure and few treatment options. There is a strong link between the microbiome–gut–brain axis and PD. PBM in animal models can reduce the signs of PD and protect the neurons from damage when applied directly to the head or to remote parts of the body. In a clinical study, PBM has been shown to improve clinical signs of PD for up to 1 year.
Methods:
Seven participants were treated with PBM to the abdomen and neck three times per week for 12 weeks. Participants were assessed for mobility, balance, cognition, fine motor skill, and sense of smell on enrolment, after 12 weeks of treatment in a clinic and after 33 weeks of home treatment.
Results:
A number of clinical signs of PD were shown to be improved by remote PBM treatment, including mobility, cognition, dynamic balance, spiral test, and sense of smell. Improvements were individual to the participant. Some improvements were lost for certain participants during at-home treatment, which coincided with a number of enforced coronavirus disease 2019 (COVID-19) pandemic lockdown periods.
Conclusions:
Remote application of PBM was shown to be an effective treatment for a number of clinical signs of PD, with some being maintained for 45 weeks, despite lockdown restrictions. Improvements in clinical signs were similar to those seen with the application of remote plus transcranial PBM treatment in a previous study.
RoccaWA.The burden of Parkinson's disease: a worldwide perspective. Lancet Neurol, 2018; 17:928–929.
2.
VictorinoDB, Guimarães-MarquesM, NejmM, ScorzaFA, ScorzaCA. COVID-19 and Parkinson's disease: are we dealing with short-term impacts or something worse?. J Parkinsons Dis, 2020; 10:899.
3.
BeauchampLC, FinkelsteinDI, BushAI, EvansAH, BarnhamKJ. Parkinsonism as a third wave of the COVID-19 pandemic?. Journal of Parkinson's Disease J Parkinsons Dis, 2020; 10:1343–1353.
4.
YangW, HamiltonJL, KopilC, et al.Current and projected future economic burden of Parkinson's disease in the U.S. NPJ Parkinsons Dis, 2020; 6:15.
ScheperjansF, DerkinderenP, BorghammerP. The gut and Parkinson's disease: hype or hope?. J Parkinsons Dis, 2018; 8:S31–S39.
7.
ForsythCB, ShannonKM, KordowerJH, et al.Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One, 2011; 6:e28032.
8.
LubomskiM, DavisRL, SueCM. The gut microbiota: a novel therapeutic target in Parkinson's disease?. Parkinsonism Relat Disord, 2019; 66:265–266.
9.
XueL-J, YangX-Z, TongQ, et al.Fecal microbiota transplantation therapy for Parkinson's disease: a preliminary study. Medicine, 2020; 99:e22035.
10.
DuPontHL, SuescunJ, JiangZ-D, et al.Microbiome characterization and reversal of dysbiosis in Parkinson's disease by fecal microbiota transplantation (1825). Neurology, 2020; 94:1825.
11.
HegelmaierT, LebbingM, DuschaA, et al.Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson's disease. Cells, 2020; 9:376.
12.
TamtajiOR, TaghizadehM, Daneshvar KakhakiR, et al.Clinical and metabolic response to probiotic administration in people with Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr, 2019; 38:1031–1035.
13.
BensonP, KimJY, RiverosC, CampA, JohnstoneDM. Elucidating the time course of the transcriptomic response to photobiomodulation through gene co-expression analysis. J Photochem Photobiol B, 2020; 208:111916.
14.
HamblinMR.Mechanisms and mitochondrial redox signaling in photobiomodulation. Photochem Photobiol B, 2018; 94:199–212.
15.
HamblinMR.Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys, 2017; 4:337–361.
16.
KhanI, TangE, AranyP. Molecular pathway of near-infrared laser phototoxicity involves ATF-4 orchestrated ER stress. Sci Rep, 2015; 5:10581.
17.
MoroC, TorresN, ArvanitakisK, et al.No evidence for toxicity after long-term photobiomodulation in normal non-human primates. Exp Brain Res, 2017; 235:3081–3092.
18.
JohnstoneDM, MitrofanisJ, StoneJ. Targeting the body to protect the brain: inducing neuroprotection with remotely-applied near infrared light. Neural Regen Res, 2015; 10:349–351.
19.
LiebertA, BicknellB, AdamsR. Protein conformational modulation by photons: a mechanism for laser treatment effects. Med Hypotheses, 2014; 82:275–281.
20.
BlattA, Elbaz-GreenerGA, TubyH, et al.Low-level laser therapy to the bone marrow reduces scarring and improves heart function post-acute myocardial infarction in the pig. Photomed Laser Surg, 2016; 34:516–524.
21.
KimB, BrandliA, MitrofanisJ, StoneJ, PurushothumanS, JohnstoneDM. Remote tissue conditioning—an emerging approach for inducing body-wide protection against diseases of ageing. Ageing Res Rev, 2017; 37:69–78.
22.
MoroC, MassriNE, TorresN, et al.Photobiomodulation inside the brain: a novel method of applying near-infrared light intracranially and its impact on dopaminergic cell survival in MPTP-treated mice. J Neurosurg, 2014; 120:670–683.
23.
JohnstoneD, ColemanK, MoroC, et al.The potential of light therapy in Parkinson's disease. ChronoPhysiol Ther, 2014; 4:1–14.
24.
GordonLC, JohnstoneDM. Remote photobiomodulation: an emerging strategy for neuroprotection. Neural Regen Res, 2019; 14:2086.
25.
StoneJ, JohnstoneD, MitrofanisJ. The helmet experiment in Parkinson's disease: an observation of the mechanism of neuroprotection by near infra-red light. In: 9th WALT Congress. E-L Laakso, C Young, (eds.). Medimond, Bologna, Italy 2013, pp. 17–20.
26.
GaneshanV, SkladnevNV, KimJY, MitrofanisJ, StoneJ, JohnstoneDM. Pre-conditioning with remote photobiomodulation modulates the brain transcriptome and protects against MPTP insult in mice. Neuroscience, 2019; 400:85–97.
27.
LimaAAM, SpínolaLG, BaccanG, et al.Evaluation of corticosterone and IL-1β, IL-6, IL-10 and TNF-α expression after 670-nm laser photobiomodulation in rats. Lasers Med Sci, 2014; 29:709–715.
28.
Al Amir DacheZ, OtandaultA, TanosR, et al.Blood contains circulating cell-free respiratory competent mitochondria. FASEB J, 2020; 34:3616–3630.
29.
LiebertA, BicknellB, JohnstoneD, GordonL, KiatH, HamblinM. “Photobiomics”: can photobiomodulation alter the microbiome?. Photobiomodul Photomed Laser Surg, 2019; 37:681–693.
30.
LiebertA, BicknellB, LaaksoE-L, et al.Improvements in clinical signs of Parkinson's disease using photobiomodulation: a prospective proof-of-concept study. BMC Neurol, 2021; 21:256.
31.
NormanGR, SloanJA, WyrwichKW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care, 2003; 41:582–592.
32.
NaeserMA, ZafonteR, KrengelMH, et al.Significant improvements in cognitive performance post-transcranial, red/near-infrared light-emitting diode treatments in chronic, mild traumatic brain injury: open-protocol study. J Neurotrauma, 2014; 31:1008–1017.
33.
LamartiniereR, BergeronR, Aung-DinR, BennettM, StephanW, BanasL. Chapter 42—Photobiomodulation treatment for brain disorders: posttraumatic stress disorder (PTSD) and dementia. In: Photobiomodulation in the Brain. MR Hamblin, Y-Y Huang (eds.). Cambridge, MA: Academic Press, 2019; pp. 589–597.
34.
SchifferF, JohnstonAL, RavichandranCT, et al.Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety. Behav Brain Funct, 2009; 5:46.
35.
SaltmarcheAE, NaeserMA, HoKF, HamblinMR, LimL. Significant improvement in cognition in mild to moderately severe dementia cases treated with transcranial plus intranasal photobiomodulation: case series report. Photomed Laser Surg, 2017; 35:432–441.
36.
HamiltonCL, El KhouryH, HamiltonD, NicklasonF, MitrofanisJ. “Buckets”: early observations on the use of red and infrared light helmets in Parkinson's disease patients. Photobiomodul Photomed Laser Surg, 2019; 37:615–622.
37.
HamiltonC, HamiltonD, NicklasonF, MitrofanisJ. Transcranial photobiomodulation therapy: observations from four movement disorder patients. In: Photobiomodulation in the Brain. M Caldieraro, P Cassano (eds.). Cambridge, MA: Elsevier, 2019; pp. 463–472.
AarslandD, KurzMW. The epidemiology of dementia associated with Parkinson's disease. Brain Pathol, 2010; 20:633–639.
40.
SeppiK, Ray ChaudhuriK, CoelhoM, et al.Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. Mov Disord, 2019; 34:180–198.
41.
BermanMH, HalperJP, NicholsTW, JarrettH, LundyA, HuangJH. Photobiomodulation with near infrared light helmet in a pilot, placebo controlled clinical trial in dementia patients testing memory and cognition. J Neurol Neurosci, 2017; 8:176.
42.
KlopfensteinT, TokoL, RoyerP-Y, LepillerQ, GendrinV, ZayetS. Features of anosmia in COVID-19. Méd Mal Infect, 2020; 50:436–439.
43.
CamargoCHF, JobbinsVA, SerpaRA, BerbetzFA, SabatiniJS, TeiveHAG. Association between olfactory loss and cognitive deficits in Parkinson's disease. Clin Neurol Neurosurg, 2018; 173:120–123.
44.
HaehnerA, BoesveldtS, BerendseH, et al.Prevalence of smell loss in Parkinson's disease–a multicenter study. Parkinsonism Relat Disord, 2009; 15:490–494.
45.
FullardME, MorleyJF, DudaJE. Olfactory dysfunction as an early biomarker in Parkinson's disease. Neurosci Bull, 2017; 33:515–525.
46.
ReesRN, NoyceAJ, SchragA. The prodromes of Parkinson's disease. Eur J Neurosci, 2019; 49:320–327.
47.
MorleyJF, CohenA, Silveira-MoriyamaL, et al.Optimizing olfactory testing for the diagnosis of Parkinson's disease: item analysis of the university of Pennsylvania smell identification test. NPJ Parkinsons Dis, 2018; 4:2.
48.
SalehpourF, HamblinMR, DiDuroJO. Rapid reversal of cognitive decline, olfactory dysfunction, and quality of life using multi-modality photobiomodulation therapy: case report. Photobiomodul Photomed Laser Surg, 2019; 37:159–167.
49.
JankovicJ.Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry, 2008; 79:368–376.
50.
LiebertA.Emerging applications of photobiomodulation therapy: the interaction between metabolomics and the microbiome. Photomed Laser Surg, 2018; 36:515–517.
51.
JohnstoneD, El MassriN, MoroC, et al.Indirect application of near infrared light induces neuroprotection in a mouse model of parkinsonism–an abscopal neuroprotective effect. Neuroscience, 2014; 274:93–101.
52.
CassanoP, PetrieS, HamblinM, HendersonT, IosifescuD. Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis. Neurophotonics, 2016; 3:031404.
53.
ZomorrodiR, LoheswaranG, PushparajA, LimL. Pulsed near infrared transcranial and intranasal photobiomodulation significantly modulates neural oscillations: a pilot exploratory study. Sci Rep, 2019; 9:1–11.
54.
TchkoniaT, MorbeckDE, Von ZglinickiT, et al.Fat tissue, aging, and cellular senescence. Aging Cell, 2010; 9:667–684.
55.
HouserMC, TanseyMG. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis?. NPJ Parkinsons Dis, 2017; 3:3.
56.
BicknellB, LiebertA, JohnstoneD, KiatH. Photobiomodulation of the microbiome: implications for metabolic and inflammatory diseases. Lasers Med Sci, 2018; 34:317–327.
57.
ChenQ, JinpengWU, DongX, et al.Gut flora-targeted photobiomodulation therapy improves senile dementia in an Aß-induced Alzheimer's disease animal model. J Photochem Photobiol B, 2021; 216:112152.
58.
LubomskiM, TanAH, LimS-Y, HolmesAJ, DavisRL, SueCM. Parkinson's disease and the gastrointestinal microbiome. J Neurol, 2020; 267:2507–2523.
59.
van IJzendoornSC, DerkinderenP. The intestinal barrier in Parkinson's disease: current state of knowledge. J Parkinsons Dis, 2019; 9:S323–S329.
FuP, GaoM, YungKKL. Association of intestinal disorders with Parkinson's disease and Alzheimer's disease: a systematic review and meta-analysis. ACS Chem Neurosci, 2019; 11:395–405.
63.
LiuB, FangF, PedersenNL, et al.Vagotomy and Parkinson disease: A Swedish register–based matched-cohort study. Neurology, 2017; 88:1996–2002.
64.
HorsagerJ, AndersenKB, KnudsenK, et al.Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. Brain, 2020; 143:3077–3088.
65.
TernákG, KutiD, KovácsKJ. Dysbiosis in Parkinson's disease might be triggered by certain antibiotics. Med Hypotheses, 2020; 137:109564.
66.
MertsalmiTH, PekkonenE, ScheperjansF. Antibiotic exposure and risk of Parkinson's disease in Finland: a nationwide case-control study. Mov Disord, 2020; 35:431–442.
67.
DuttaSK, VermaS, JainV, et al.Parkinson's disease: the emerging role of gut dysbiosis, antibiotics, probiotics, and fecal microbiota transplantation. J Neurogastroenterol Motil, 2019; 25:363.
68.
UyarGÖ, YildiranH. A nutritional approach to microbiota in Parkinson's disease. Biosci Microbiota Food Health, 2019; 38:115–127.
69.
KaelbererMM, BuchananKL, KleinME, et al.A gut-brain neural circuit for nutrient sensory transduction. Science, 2018; 361:eaat5236.
70.
YouH, MarianiL-L, MangoneG, Le Febvre de NaillyD, Charbonnier-BeaupelF, CorvolJ-C. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease. Cell Tissue Res, 2018; 373:111–135.
71.
Shumway-CookA, BrauerS, WoollacottM. Predicting the probability for falls in community-dwelling older adults using the Timed Up Go Test. Physical Therapy, 2000; 80:896–903.
72.
LangJT, KassanTO, DevaneyLL, Colon-SemenzaC, JosephMF. Test-retest reliability and minimal detectable change for the 10-meter walk test in older adults with Parkinson's disease. J Geriatric Physical Therapy, 2016; 39.
73.
HillK, BernhardtJ, McGannA, MalteseD, BerkovitsD. A new test of dynamic standing balance for stroke patients: reliability, validity, and quantitative clinical tests. Physiotherapy Canada, 1996; 47:257–262.
74.
GillDJ, FreshmanA, BlenderJA, RavinaB. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Movement Disorders, 2008; 23:1043–1046.
75.
PullmanSL.Spiral analysis: a new technique for measuring tremor with a digitizing tablet. Movement Disorders, 1998; 13:85–89.
76.
EarhartGM, CavanaughJT, EllisT, FordMP, ForemanKB, DibbleL. The 9-hole PEG test of upper extremity function: average values, test-retest reliability, and factors contributing to performance in people with Parkinson disease. J Neurol Phys Ther, 2011; 35:157–163.
77.
SmithsonF, MorrisME, IansekR. Performance on clinical tests of balance in Parkinson's disease. Phys Ther, 1998; 78:577–592.
78.
DotyRL. The Smell Identification Test administration manual, 2013. Haddon Heights, NJ: Sensonics.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
